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To address the subtle interactions between antiviral cytotoxic T-cell (CTL) immune responses and the evolution of viral
quasispecies variants in vivo, we performed a longitudinal study in a simian immunodeficiency virus (SIV)-infected rhesus
macaque that had a long experimental SIV infection before developing simian AIDS. Before being infected with SIV, this
animal was immunized with a mixture of seven lipopeptides derived from SIV Nef and Gag proteins and showed a bispecific
antiviral CTL response directed toward Nef 169–178 and 211–225 peptides. After SIV infection, CTL activity against the Nef
169–178 epitope was no longer detectable, as assessed from peripheral blood mononuclear cells stimulated by autologous
SIV. CTL activity against the 211–225 epitope was lost after 3 months, and an additional CTL response to the amino acids
112–119 Nef epitope emerged. Analysis of the Nef proviral sequence revealed the presence of immune escape variants first
in the 211–225 epitope and much later in the 112–119 epitope. In contrast, epitope 169–178 showed only two mutations
among all viral sequencing performed. We conclude that in this macaque, bispecific CTL exerted a strong selective pressure
and escape virus mutants finally emerged. We identified CTL recognizing a conserved Nef epitope 112–119 (SYKLAIDM),
essential for viral replication, which could be associated with a prolonged AIDS-free period. These results stress the
importance of the induction of broader multispecific CTLs directed against highly conserved and functional T-cell epitopes
by vaccination, with the aim of keeping HIV infection in check. © 2000 Academic Press
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iINTRODUCTION
The rate of progression to AIDS in human and simian
immunodeficiency virus (HIV and SIV) infections is highly
variable and depends on a complex series of interac-
tions between the host and virus. Growing evidence
indicates that antiviral CD81 cytotoxic T-lymphocyte
(CTL) activities are an important determinant in the con-
trol of primary viremia and in retarding the onset of
disease in infected subjects (Jin et al., 1999; Kuroda et al.,
1999; Schmitz et al., 1999). It has also been shown that
the presence of CTLs in HIV patients is inversely corre-
lated with the plasma viral load, highlighting the positive
role of this cellular-mediated immune function in control-
ling virus replication (Ogg et al., 1998). Moreover, CTLs
may be responsible for protection against HIV infection
in a significant proportion of African women with docu-
mented persistent HIV exposure, while remaining nega-
tive for plasma HIV antibodies (Kaul et al., 2000; Row-
land-Jones et al., 1998). In addition, cytotoxic responses1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 33-01-40-51-65-35. E-mail: bourgault@cochin.inserm.fr.
551ere associated with protection against viral challenge
n lentivirus animal models (Flynn et al., 1996; Gallimore
t al., 1995) and were probably implicated in the protec-
ion or in the containment of infection, without any role of
eutralizing antibodies (Cafaro et al., 1999; Robinson et
l., 1999).
The biological relevance of CTL activities on the viral
uasispecies population in vivo was demonstrated in
tudies of HIV-infected persons that showed a strong
onospecific CTL response inducing a positive selec-
ion for viral escape mutants in primary (Borrow et al.,
997; Price et al., 1997) and late-stage HIV infections
Goulder et al., 1997). In this latter study (Goulder et al.,
997), the selection of escape mutants appeared to co-
ncide with an increase in viral load, a decline in CD41 T
cells, and a progression to AIDS. Moreover, we previ-
ously reported that the induction of a monospecific anti-
Nef CTL response by a lipopeptide vaccine in macaques
led to the selection of a less immunogenic preexisting
minor variant virus and subsequently to the emergence
of an escape mutant virus (Mortara et al., 1998).Because the narrow oligoclonal CTLs may exert con-
siderable selective pressure, many groups have made
0042-6822/00 $35.00
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552 MORTARA ET AL.the effort to induce antiviral multispecific CTL responses
using different vaccinal approaches to control chal-
lenges by SIV, Simian/Human Immunodeficiency Virus
(SHIV), or HIV in animal models (Hanke et al., 1998;
Mortara et al., 1999; Woodberry et al., 1999). Indeed,
multispecific CTLs may have more chance of recognizing
important determinants located in highly functionally and
conserved viral regions, and the probability of CTL es-
cape mutations occurring without concomitantly damag-
ing the fitness of the virus itself is low. It has been also
demonstrated that polyclonality of anti-HIV CTLs is pos-
itively correlated with the CD41 T-cell counts and with a
etter clinical status (Dalod et al., 1999).
The rhesus macaque SIV model provides excellent
ossibilities for testing immunogenic formulations for
ffective vaccine development against HIV infection, as
ell as for further studying the fine equilibrium between
irus and host in the pathogenesis of AIDS. In this study,
o investigate the effects of sequence variation and pos-
ible escape from CTL recognition on the containment of
IV replication and its relationship with disease progres-
ion, we analyzed CTL responses in a long-term progres-
or macaque immunized by lipopeptides and then in-
ected with SIV. We demonstrated that the slow progres-
ion of infection was concomitant with the presence of
nti-Nef bispecific CTLs. We identified a CTL conserved
ef epitope, essential for viral replication, that appeared
o be a critical factor in the disease outcome.
RESULTS AND DISCUSSION
We analyzed the CTL response and its evolution over
ime in one vaccinated and then infected macaque (C15)
hat showed a long asymptomatic period before devel-
ping AIDS. This macaque was initially immunized with
even lipopeptides derived from SIV Nef and Gag pro-
eins as described in Materials and Methods. The vac-
ine-induced CTL responses were examined by stimu-
ating macaque peripheral blood mononuclear cells (PB-
Cs) with a mixture of the corresponding seven long
ree peptides and testing them against autologous B-LCL
ensitized with the same long peptides. After immuniza-
ion, this macaque recognized two long peptides within
he Nef protein [amino acids (aa) 155–178 and 201–225]
data not shown). The shorter peptides recognized by
ffector cells were determined by sensitizing autologous
-LCL target cells with short peptides, which were sub-
equently tested in a 51Cr release test (CRT). We identi-
fied two peptides recognized by the C15 CTLs: Nef 169–
178, KTFGWLWKLV, and Nef 211–225, LAWKFDPTLAYT-
YEA (Figs. 1a and 1b). No other anti-Nef or -Gag CTL
activities were found, in particular against peptide Nef
112–119 (Fig. 1c). Autologous B-LCL target cells infected
with Nef-recombinant vaccinia virus were lysed by anti-
Nef 169–178 and anti-Nef 211–225 CTLs, respectively,suggesting that these peptides were naturally processed
(data not shown).
On the day of the CRT, effector cells were .75% CD81
T cells, as might be expected for class I-restricted
epitope-specific CTLs. In addition, these cytotoxic activ-
ities did not represent an in vitro induction of primary
CTL responses, as there were no CTL responses after
the antigen-specific stimulation of naive PBMCs from
this macaque (data not shown).
After SIV challenge, the macaque became infected,
and we characterized the evolution of anti-Nef cytotoxic
FIG. 1. Analysis of CTL responses after lipopeptidic immunization.
Effector cells were obtained by stimulating PBMCs with the pool of
seven free peptides as described in Materials and Methods. Target
cells were autologous B-LCLs alone (None) or incubated with (a)
peptide Nef 169–178, (b) peptide Nef 211–225, and (c) peptide Nef
112–119. Mean values for 51Cr released from target cells are expressed
as percentage of specific lysis.T-cell responses by activating PBMCs with concanavalin
A (ConA) mitogen, which is capable of stimulating autol-
N
N
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553TEMPORAL LOSS OF Nef-EPITOPE CTLogous SIV-infected cells, as described previously (Mort-
ara et al., 1998). Three months after the challenge, CTLs
recognized targets sensitized by the peptide Nef 211–225
(Fig. 2a) but no longer recognized targets sensitized by
the Nef 169–178 peptide (Fig. 2d). We also found another
CTL specificity against the Nef protein sequence 101–
126 (data not shown). By using short peptides, we were
able to identify a third new epitope: Nef 112–119,
SYKLAIDM (Fig. 2g).
These results indicate that the two peptides recog-
nized by anti-SIV autologous CTLs (vaccinal epitope, Nef
211–225, and viral epitope, Nef 112–119) are probably
immunodominant in the Nef protein in this infected ma-
caque. To confirm the hierarchy of immunodominance of
these two epitopes and to precisely define the magni-
tude of these responses, we carried out a limiting dilu-
tion analysis and determined the epitope-specific CTL
precursor (CTLp) frequencies against the three different
Nef peptides. As shown in Table 1, the frequencies of
FIG. 2. Evolution of antipeptide CTL activities after SIV infection. CT
3 months (a, d, g), 12 months (b, e, h), and 37 months (c, f, i) after SIV in
peptide Nef 211–225 (a–c), peptide Nef 169–178 (e, f), or peptide Nef 112
peptide was not yet determined at the time of the experiment.CTLp against Nef 211–225 and Nef 112–119 were already
high 15 days postinfection, and they remained signifi-cantly elevated within the 3 first months. Conversely, the
CTLp anti-Nef 169–178 was weak soon after infection
and did not persist later. Together, these data confirm
that the anti-Nef cytotoxic activities in this infected ma-
caque were characterized by a codominant CTL reactiv-
ity.
TABLE 1
Number of Anti-Peptide CTLp/106 PBMCs
Anti-peptide
CTLp Naivea
Post-SIV infectionb
Day
15
Month
1
Month
2
Month
3
EF 169–178 1.2 3.6 19.8 1 NT
EF 211–225 2 18 26.3 66 8.3
EF 112–119 3.8 28 NDc 40 38.5
a Number of anti-peptides CTLp obtained from naive PBMCs.
b Number of anti-peptides CTLp obtained at 15 days and 1, 2, or 3
obtained by stimulating PBMCs with autologous SIV-infected cells at
. Target cells were autologous B-LCLs alone (none) or incubated with
–i). (d) Peptide Nef 170–178 was used because the optimal Nef 169–178L were
fectionmonths after SIVmac251 inoculation.
c ND 5 Not Determined.
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554 MORTARA ET AL.Recent in vivo CD81 T-cell depletion experiments in
the SIV-macaque model have demonstrated the crucial
role of this type of immune response in the control of SIV
replication during either primary or chronic infection
(Schmitz et al., 1999). Indeed, macaques treated with
anti-CD8 monoclonal antibody during chronic SIV infec-
tion showed a dramatic rise in plasma viremia, which
decreased with the reappearance of SIV-specific CD81 T
ells (Schmitz et al., 1999). Moreover, it has been showed
hat the early clearance of SIVmac occurs concomitantly
ith the emergence of the CTL response (Kuroda et al.,
999). These data highlight the central role of virus-
pecific CD81 CTLs in the containment of virus replica-
tion. It has also been reported that strong monospecific
CTLs can exert considerable selective pressure in both
primary and late-stage HIV infections and that they may
select escape mutant viruses (Borrow et al., 1997; Goul-
der et al., 1997; Price et al., 1997). Furthermore, we have
demonstrated that the induction by lipopeptides of CD81
CTLs recognizing one Nef epitope (aa 128–137,
GLEGIYYSAR) in two macaques, C16 and C18, led to the
selection of a less immunogenic variant virus 5 months
after infection and to the emergence of an escape mutant
virus by 12 months in one macaque (Mortara et al., 1998).
Concomitant with the appearance of variant selection,
there was a rise in viremia that remained high until the
development of simian AIDS and death in these two
macaques. Interestingly, macaque C18, which developed
an escape mutant virus, showed an AIDS disease out-
come much faster (16 months) than macaque C16 (29
months) (Table 2). For macaque C15, we showed that
Nef-specific codominant CTLs were found during the
first 3 months after SIV infection, and we wanted to see
whether this bispecific CTL response prevented the ap-
pearance of viral variants or mutants, which was asso-
ciated with good control of viral replication (Table 2).
As of the 12th month postinfection, the anti-211–225
Nef CTL specificity was lost (Figs. 2b and 2c) even
though the anti-112–119 Nef CTL activity was detectable
(Fig. 2h). The latter was lost at months 31 and 37 (not
shown and Fig. 2i). The reappearance of anti-169–178
Nef CTL specificity was effective at month 37 (Figs. 2e
and 2f). Finally, despite this weak cytotoxic activity, there
was a rise in the virus replication and development of
AIDS at the 38th month (Table 2).
In order to test the hypothesis of a viral escape muta-
tion in the Nef epitopic sequence, we analyzed complete
Nef proviral DNA obtained from the PBMCs by amplifi-
cation, cloning, and sequencing at two time points
postinfection: months 10 and 36 (Figs. 3–5). The viral
sequences of the Nef gene coding for the 201–225 pep-
tide in nine clones obtained 10 months postinfection
showed the presence of two mutant viruses, represent-
ing 100% of the new virus population in the 211–225
epitope: A 3 V 212 (44%) or K 3 R 214 (55%) (Fig. 3).
Sequencing at 36 months showed the selection of one
m
avirus mutant with an arginine at position 214 (presented
in 87% of clones sequenced) (Fig. 3).
With regard to the 112–119 CTL Nef epitope, it is
important to note that the virus isolate SIVmac251 had a
serine at position 112 (112–119/112S), in contrast to the
molecular clone BK-28 and immunizing sequences,
which had a threonine at this position (112–119/112T).
Proviral sequencing of the 101–126 Nef immunizing se-
quence at month 10 revealed four mutations: two in the
epitope, S3 T 112 (10%) and M3 T 119 (10%); and two
n the flanking regions, T,A3 P 110 (100%) and F3 L 122
100%) (Fig. 4). At month 36, we could find four mutations
n the epitope: S3 T 112 (87%), L3 M 115 (12.5%), I 3
117 (12.5%), and M 3 L 119 (50%).
In contrast, the 169–178 epitope and its flanking re-
ions showed only two mutations among all viral se-
uencing performed (Fig. 5). Epitope Nef 169–178 ap-
ears to be an epitope that was not submitted to the
ressures of selection.
The modified epitopes could have escaped CTL sur-
eillance in several ways. Antigen processing and the
ransport of peptides may be affected by mutations
ithin the flanking regions (Couillin et al., 1994 and 1995;
isenlohr et al., 1992), peptide binding to MHC may be
ltered by mutations in the anchor residues (Couillin et
l., 1994; Phillips et al., 1991; Pircher et al., 1990), and,
inally, mutations may affect recognition by T-cell recep-
ors (TCRs). Mutations that affect recognition by TCRs
TABLE 2
Cellular Viremia Measured by Coculture of PBMCs
with CEM 3 174
Time post-SIV
Rhesus macaque
C15 C16 C18
Day 7 750 1250 750
Month 1 10 10 30
Month 3 0 10 2
Month 5 0 130 50
Month 7 0 50 250
Month 9 1.5 50 150
Month 11 0.5 50 50
Month 13 0 150 150
Month 16 ND ND AIDS
Month 22 6 50
Month 29 ND AIDS
Month 31 10
Month 35 10
Month 37 25
Month 38 AIDS
Note. The number indicates the dilution of PBMCs up to which
coculture was positive. Three macaques were tested: C15 was studied
in the present report and C16 and C18 were previously studied in
Mortara et al. (1998). ND indicates Not Determined.ay lead to nonrecognition by CTLs (Lill et al., 1992) or to
n additional escape mechanism by antagonism and
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555TEMPORAL LOSS OF Nef-EPITOPE CTLanergy of effector cells (Bertoletti et al., 1994; Jameson et
al., 1993; Kent et al., 1997; Klenerman et al., 1994; Sloan-
ancaster et al., 1993).
Therefore, we analyzed the impact of changes within
the two codominant Nef epitopic sequences on CTL
activity in vitro. Antipeptide CTL lines were obtained by
stimulating PBMCs with the Nef 211–225 and Nef 112–
119 peptides. First, we tested the ability of anti-211–225
CTL lines to recognize and lyse autologous targets sen-
sitized with the various Nef peptides (index peptide, A3
V 212 and K 3 R 214). As shown in Fig. 6a, cytotoxic T
cells recognized autologous target cells sensitized with
the peptide A 3 V 212, although the activity was much
lower than that observed against target cells sensitized
with the index peptide. In addition, peptide 214R was not
recognized at all. These results suggest that mutations in
a CTL epitope can occur under CTL pressure and may
allow the virus to escape CTL recognition, as recently
shown by Evans et al. (1999). To gain further insight into
the molecular mechanism of CTL–peptide interaction,
we tested the ability of the anti-peptide 211–225 CTL line
to recognize and lyse B-LCL target cells sensitized by
peptide 212V in a dilution peptide assay. CTL lines were
established by stimulating PBMCs with the index peptide
and tested on autologous target cells sensitized with
serial dilutions of peptides 212A (index peptide) and 212V
ranging from 1025 to 1028 M. The 50% of maximal lysis
26
FIG. 3. Sequence of viral clones isolated from PBMCs of infected mac
Analysis was performed within the sequence coding for Nef 201–225 p
for synthesis of lipopeptides. Eleven clones were sequenced from inoas obtained with a peptide dilution of 0.5 3 10 M for
ndex peptide, and the impairment of CTL response was
a
p0.5 log10 for peptide 212V (Fig. 6b). This suggests that the
changes in the amino acid sequence did alter the inter-
action among the MHC, peptide, and TCR within this
three-molecular complex of antigen recognition.
Second, we tested the ability of the anti-112–119/112T
CTL line to recognize and lyse autologous targets sen-
sitized with the various Nef peptides (112T, 112S, 115M,
119L, and 117V). Peptide 112S was well recognized by
cytotoxic T cells, whereas peptides 115M, 117V, and 119L
were recognized with a much lower lysis. Figure 6c
showed that the dilution peptide assay allowing 50% of
maximal lysis from the anti-112T peptide CTL line against
the 112S viral peptide was high, 5 3 10210 M, and that
here was an impairment of lysis of 1–2.5 log10 against
argets pulsed with mutant peptides L, V, and M, respec-
ively.
Together these results indicate that changes in the
mino acid sequences within a CTL epitope were able to
ffect antigen recognition, leading to an impairment of
TL function. Interestingly, in this long-term progressor
acaque, the virus acquired a selective advantage only
fter 12 months by progressively escaping CTL activity
s shown by the increasing percentage of viral mutants.
election of mutants in the 112–119 epitope was slower
han in the 211–225 epitope.
In fact, theoretically, there was a very strong cytotoxic
cell-mediated selective pressure on epitope 112–119,
t 10 and 36 months after challenge with pathogenic isolate SIVmac251.
The first line represents the sequence of molecular clone BK28 used
SIVmac251, and 8 of the 11 clones were similar to BK28 clone.aque as observed by high frequencies of specific CTLp ap-
earing soon after infection and by the quasiabsence of
556 MORTARA ET AL.FIG. 4. Sequence of viral clones isolated from PBMCs of infected macaque at 10 and 36 months after challenge with pathogenic isolate SIVmac251.
Analysis was performed within the sequence coding for Nef 101–126 peptide. The first line represents the sequence of molecular clone BK28 used
for synthesis of lipopeptides. Eleven clones were sequenced from inoculum SIVmac251.
FIG. 5. Sequence of viral clones isolated from PBMCs of infected macaque at 10 and 36 months after challenge with pathogenic isolate SIVmac251.
Analysis was performed within the sequence coding for Nef 155–178 peptide. The first line represents the sequence of molecular clone BK28 used
for synthesis of lipopeptides. Eleven clones were sequenced from inoculum SIVmac251, and 8 of the 11 clones were similar to BK28 clone.
pptide N
he diffe
557TEMPORAL LOSS OF Nef-EPITOPE CTLvariation within this Nef epitope in more than 60 clones
studied that were collected at various times after infec-
tion from the two macaques C16 and C18 of our previous
study, which had a monospecific CTL response against
epitope Nef 128–137 (data not shown). However, the
112–119 (SYKLAIDM) Nef CTL epitope shares five resi-
dues of an important and conserved region in the N-
terminal portion of the Nef protein, known to be a poten-
tial protein kinase C phosphorylation site: VPLRTM-
SYKLA, aa 106–116 (Huang et al., 1995; Myers et al., 1993;
Shugars et al., 1993). Moreover, recent findings have
strongly suggested that this region and the acidic ele-
ment: MDDIDEEDDDL, aa 87–97, within SIV Nef are
important for its function and, in particular, for down-
regulating cell surface expression of CD4 and MHC
FIG. 6. Anti-peptide CTL responses against viral variants. (a) Anti-Ne
ulsed with the original peptide Nef 211–225 (}), with the mutant pep
without peptide (3). (b) Anti-Nef 221–225 CTL lines were tested against
peptide Nef 221–225/212V (). Target cells were preincubated for 1 h w
lines were tested against autologous target cells pulsed with the origi
(}), with the mutant peptide Nef 112–119/115M ( n ), with the mutant pe
Target cells were preincubated for 1 h with 10-fold serial dilutions of tclass I and altering T-cell signaling (Carl et al., 1999).
One intriguing hypothesis is that this particular epitope,located within a sequence required for efficient viral repli-
cation, may inhibit or prevent the emergence of CTL escape
variants, as has been recently proposed for one highly
conserved HLA-B14-restricted CTL epitope in the HIV-1 p24
protein (aa 298–307) (Harrer et al., 1996; Wagner et al.,
1999). This specificity has been documented to be a pro-
tective prognostic factor for HIV-1-infected patients (Kaslow
et al., 1996; Malkovsky et al., 1996), and the emergence of
sequence variation in this epitope was inhibited by the
negative effects on viral replication (Wagner et al., 1999). In
our study, the appearance of four viral mutations in con-
served 112–119 Nef epitope suggests a strong selection
pressure exerted by CTL on this site. In addition, the rec-
ognition by CTLs of Nef regions essential for viral replica-
tion could be associated with a protective prognostic factor
25 CTL lines were tested at month 10 against autologous target cells
f 211–225/214R (n ), with the mutant peptide Nef 211–225/212V (), or
ous target cells pulsed with the original peptide (}) or with the mutant
fold serial dilutions of the different peptides. (c) Anti-Nef 112–119 CTL
tide Nef 112–119/112T ( ), with the mutant peptide Nef 112–119/112S
ef 112–119/119L (), or with the mutant peptide Nef 112–119/117V (3).
rent peptides.f 221–2
tide Ne
autolog
ith 10-
nal pepfor SIV-infected macaques.
In conclusion, our results support the idea that multi-
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558 MORTARA ET AL.specific immunodominant CTL responses directed
against functionally and highly conserved viral regions,
particularly within the Nef protein, need to be obtained
for the development of an efficacious anti-HIV vaccine.
MATERIALS AND METHODS
Sequences and synthesis of lipopeptides
Five peptides from the SIV NEF protein were synthe-
sized: LP1 aa 101–126, LP2 aa 125–147, LP3 aa 155–178,
LP4 aa 201–225, and LP5 aa 221–247. Two peptides from
the SIV GAG protein were also produced: LP6 aa 165–
195 and LP7 aa 246–281. The selected sequences were
identical to the sequences that have been previously
reported (Bourgault et al., 1994) but were modified in the
C-terminal position by the enantiomerically pure N e-
palmitoyl-lysylamide. The lipopeptides were synthesized
by solid-phase synthesis as previously described
(Deprez et al., 1996). The lipopeptides were purified to
.90% homogeneity by reverse-phase HPLC and charac-
terized by amino acid composition and molecular mass
determination.
Short peptides
Overlapping peptides spanning the entire sequence of
lipopeptides were synthesized by Neosystem (Stras-
bourg, France).
Immunization protocol
The rhesus macaque C15 (Macaca mulatta) was im-
munized by the subcutaneous injection of a mixture of
seven lipopeptides (500 mg each) in incomplete Freund’s
djuvant (IFA) on days 0, 21, and 42. Macaque C15 was
hallenged 6 months later by intravenous injection of 10
nimal-infectious dose 50 (AID50) of highly pathogenic
IVmac251 isolate. One AID50 is the dose of virus that
nfects 50% of macaques; this dose has been previously
etermined in an in vivo titration assay (A. M. Aubertin,
ersonal communication). All animal experiments were
erformed in accordance with European Union guide-
ines.
eneration of CTL lines
PBMCs were isolated by density gradient centrifuga-
ion through lymphocyte separation medium (Pharmacia,
ppsala, Sweden) and were used immediately or stored
t 2180°C in liquid nitrogen. Anti-peptide CTL lines were
btained by culturing the monkey PBMCs (2 3 106 cells/
l) in 24-well microtiter plates (Costar, Cambridge, MA)
n RPMI 1640 supplemented with 100 U/ml penicillin, 100
mg/ml streptomycin, 2 mM L-glutamine, 1% nonessential
amino acids, 1 mM sodium pyruvate, 10 mM HEPES
buffer, 2 3 1025 M 2-mercaptoethanol, and 10% heat-
inactivated fetal calf serum (FCS). A mixture of the seven
free peptides (5 mM each), corresponding to the lipopep-ide sequences, was added to each well. The plates
ere incubated for 3 days at 37°C, and interleukin-2
IL-2) (Boerhinger-Mannheim, Mannheim, Germany) was
hen added to each well (10 IU/ml). On days 7 and 14,
ffector cells were stimulated by adding fresh autolo-
ous PBMCs that had been pulsed for 2 h with the
eptide pool (5 mM each), washed, and irradiated (40 Gy)
effector-to-stimulator ratio, 1:2). The PBMCs from ma-
aques that had been challenged with SIV were col-
ected and cultured (106 cells/ml) in the same culture
edium. The production of SIV antigens on infected
D41 cells was induced by stimulating PBMCs with 10
mg/ml ConA (Sigma Chemical Co., St. Louis, MO) for 3
days. IL-2 (10 IU/ml) was then added, and cells were
diluted to 5 3 105/ml twice a week as previously de-
cribed (Miller et al., 1990).
Phenotypic analysis of CTL cell lines
Cell lines were phenotyped on the day of the CRT by
incubating cells with FITC-conjugated anti-CD4 (OKT4;
Ortho Diagnostic Systems, Raritan, NJ) and phycoerytrin-
conjugated anti-CD8 (Leu-2a; Becton Dickinson, Moun-
tain View, CA) monoclonal antibodies for 30 min at 4°C.
The cells were washed with PBS and examined for the
percentage of positive staining cells in an Epics Elite
flow cytometer (Coulter, Margency, France). Isotype-
matched irrelevant antibodies (Coulter) were used as
controls.
In vitro transformation of B cell lines
B-LCLs were generated by incubating twofold dilu-
tions of PBMCs with supernatant from the S 594 cell line.
This line (kindly provided by N. Letvin) produces the
immortalizing baboon herpes virus (Herpesvirus papio).
B-LCLs were then cultured in medium supplemented
with 10% FCS.
Recombinant vaccinia viruses
The sequence encoding the NEF protein was inserted
into the vaccinia virus (Guy et al., 1987). The wild-type
vaccinia virus, Copenhagen strain, was used as a con-
trol. All of the constructs were prepared by Transgene
(Strasbourg, France).
CRT
Target cells were sensitized with peptides. B-LCLs
(106) were incubated either overnight or for 1 h with long
r short peptides (concentration, 1025 to 1028 M), respec-
ively, at 37°C in a humidified 5% CO2 atmosphere. To
obtain target cells presenting SIVmac251 gene products,
B-LCLs were incubated at a concentration of 106 cells/ml
with recombinant vaccinia virus (20 PFU/cell) for 18 h
under identical conditions. The B-LCLs were then
washed and labeled with 100 mCi Na2
51 CrO4 (NEN Life
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559TEMPORAL LOSS OF Nef-EPITOPE CTLScience Products, Courtaboeuf Les Ullis, France) for 1 h,
washed twice, and used as target cells. The CRT was
performed in V-bottom 96-well microtiter plates. The cy-
tolytic activity of anti-SIV cell lines was measured by
mixing 5000 51Cr-labeled target cells with effector cells at
arious effector cell/target cell (E/T) ratios in a final
olume of 200 ml/well. Duplicate wells were seeded for
each E/T ratio. Plates were incubated for 4 h at 37°C; 100
ml of supernatant was then removed from each well and
analyzed with a gamma counter. Spontaneous release
was determined by incubating target cells with medium
alone; it never exceeded 20% of the total 51Cr incorpo-
ated. Results are expressed as specific Cr release:
00 3 (experimental cpm 2 spontaneous cpm)/(maxi-
um cpm 2 spontaneous cmp). The within-sample vari-
tion never exceeded 5% of the absolute cpm.
recursor frequency assay
The frequency of peptide-specific CTLp in PBMCs was
etermined by limiting dilution analysis (LDA). Briefly,
BMCs were cultured in twofold serial dilutions (12,500–
00,000 cells/well) in 100 ml of culture medium in 24
eplicates in U-bottom 96-well plates. Autologous PB-
Cs, pulsed for 2 h with each peptide (at 20 mM con-
centrations) and irradiated (40 Gy), were then set up at
5000 cells/well in 100 ml of culture medium, as stimulator
cells. Subsequently, IL-2-containing medium was added
to each microwell on days 3, 7, and 10 at a final concen-
tration of 10 IU/ml. On day 14, 100 ml of cultured cells
from each well was then transferred to 96-well plates
and incubated with 5000 51Cr-labeled B-LCL autologous
ells that had been pulsed with peptide in a standard 4-h
ytotoxicity assay (see earlier). Estimates of precursor
requency were obtained by the weighted mean method
rom the Poisson distribution relationship between the
esponding cell number and the logarithm of the percent-
ge of nonresponding (negative) culture as described by
aswell (1981). A well was considered positive, presum-
bly containing at least one CTLp, if the 51Cr release
xceeded the mean spontaneous release by 8–10% (i.e.,
lways above 3 S.D.s). The 95% confidence limit for each
requency was calculated. We verified, using the x2 test,
hat the points were aligned and that the kinetics were in
ine with the single-hit model. The x2 test was used to
etermine whether two frequencies were significantly
ifferent.
easure of cellular viremia
To quantify cellular viremia, 105 CEM 3 174 cells were
ocultured with fivefold serial dilutions of PBMCs. Super-
atants of 30-day cultures were tested for the presence
f p27 SIV Ag using a commercial Ag capture assay
Coulter).
c
aDNA preparation
PBMCs were isolated as described and washed in
RPMI medium. Aliquots (107 cells) were then incubated
vernight at 52°C in 1 ml lysis buffer (10 mM Tris–HCl,
H 8.3, 50 mM KCl, 2.5 mM MgCl2, 0.45% Tween 20, and
400 mg/ml proteinase K). The DNA was extracted with
phenol–chloroform and precipitated with ethanol. The
pellet was washed with 70% ethanol, dried, resuspended
in 10 mM Tris, pH 7.5, and quantified by measuring the
O.D. at 260 nm.
PCR amplification
Nested PCRs were performed in 100-ml reaction mix-
tures containing a 200 mM concentration of each de-
xynucleotide triphosphate (Pharmacia, Uppsala, Swe-
en), 10 mM Tris–HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2,
.5 U of Taq polymerase (GIBCO BRL, Life Technologies,
aithersburg, MD), and 20 pmol of each primer (Genset,
aris, France). The primers used in the first-round PCR
ere Nef1 (59-AGGCTCTCTGCGACCCTACG-39) and Nef2
59-AGAACCTCCCAGGGCTCAATCT-39). VJ11 (59-ATG-
GTGGAGCTATTTCCATG-39) and VJ12 (59-TTAGCCTTCT-
CTAACCTC-39) were used in the second round (repre-
enting the entire NEF gene). Each initial reaction con-
ained 1 mg DNA, and 5 ml of the first PCR round was
used in the second round. The reactions were carried
out in a DNA thermocycler 9600 (Perkin–Elmer Cetus,
Branchburg, NJ) for 40 cycles. The first step was 1 min at
96°C, with the subsequent cycle conditions being 30 s at
95°C, 30 s at 55°C, and 1 min at 72°C, with a final
incubation at 72°C for 5 min. Amplified products were
visualized on a 1.5% agarose gel after staining with
ethidium bromide.
RT–PCR
The viral isolate RNA was extracted from 400 ml of the
viral stock using 300 ml phenol acid (Appligene Oncor,
llkirch, France) and 300 ml extraction buffer (7 M urea,
.35 M NaCl, 10 mM Tris–HCl, pH 7.5, 10 mM EDTA, and
% SDS). After vortexing and centrifugation, the super-
atant was extracted twice with phenol, twice with chlo-
oform, and then ethanol precipitated with 2 mg of tRNA.
After centrifugation, the RNA pellet was washed with 70%
ethanol, dried, and resuspended in 50 ml sterile water.
Five microliters were reverse transcribed for 1 h at 37°C
in a 25-ml reaction mixture containing 50 mM Tris–HCl,
pH 8.3, 75 mM KCl, 3 mM MgCl2, 8 mM DTT, 400 mM
concentration of each dNTP, 50 pmol of primers Nef2 and
Nef1, 30 U of RNAsin (Promega, Madison, WI), and 200 U
Mo-MuLV reverse transcriptase (GIBCO BRL). The PCR
mix was incubated for 5 min at 90°C, and 5 ml of theDNA mixture was amplified in the same PCR conditions
s described here, using VJ11 and VJ12 as primers.
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560 MORTARA ET AL.Cloning and sequencing
After purification on a QiaQuick column (Qiagen,
Courtaboeuf Les Ullis, France), 50 ng of the PCR product
was ligated overnight at 15°C with 50 ng of pTAG vector
(R&D Systems Europe, Abingdon, UK) in 10 ml containing
0 mM Tris–HCl, pH 7.6, 10 mM MgCl2, 1 mM ATP, 1 mM
DTT, 5% PEG-8000, and 1 U of T4 DNA ligase (GIBCO
BRL). Then 0.1 ml of the ligation product was transformed
into Escherichia coli TG1, and the few white colonies
obtained on LB plates with ampicillin were selected.
DNA was extracted using the Easy Prep Plasmid Prep kit
(Pharmacia, Piscataway, NJ), and 500 ng was sequenced
using the Dye Terminator chemistry on a 373A se-
quencer (ABI/Perkin–Elmer, Cetus). All the sequences
obtained were aligned with the SeqEd program (PE bio-
system).
ACKNOWLEDGMENTS
This work was supported by the Agence Nationale de Recherche sur
le SIDA, the Institut Pasteur de Lille, and the Centre National de
Recherches Scientifiques. L.M. holds a Sidaction/Ensemble Contre le
SIDA fellowship. We are grateful to Isabelle Bouchaert for technical
advice in the phenotypic analysis. We wish to thank Michael Patterson
(Micelle Science) for editing the English text.
REFERENCES
Bertoletti, A., Sette, A., Chisari, F. V., Penna, A., Levrero, M., De Carli, M.,
Fiaccadori, F., and Ferrari, C. (1994). Natural variants of cytotoxic
epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells.
Nature (Lon) 369, 407–410.
Borrow, P., Lewicki, H., Wei, X., Horwitz, M. S., Peffer, N., Meyers, H.,
Nelson, J. A., Gairin, J. E., Hahn, B. H., Oldstone, M. B. A., and Shaw,
G. M. (1997). Antiviral pressure exerted by HIV-1-specific cytotoxic T
lymphocytes (CTLs) during primary infection demonstrated by rapid
selection of CTL escape virus. Nat. Med. 3, 205–211.
Bourgault, I., Chirat, F., Tartar, A., Le´vy, J. P., Guillet, J. G., and Venet, A.
(1994). Simian immunodeficiency virus as a model for vaccination
against HIV: Induction in rhesus macaques of GAG or NEF specific
cytotoxic T lymphocytes by lipopeptides. J. Immunol. 152, 2530–2537.
Cafaro, A., Caputo, A., Fracasso, C., Maggiorella, M. T., Goletti, D.,
Baroncelli, S., Pace, M., Sernicola, L., Koanga-Mogtomo, M. L., Betti,
M., Borsetti, A., Belli, R., Akerblom, L., Corrias, F., Butto, S., Heeney, J.,
Verani, P., Titti, F., and Ensoli, B. (1999). Control of SHIV-89.6P-
infection of cynomolgus monkeys by HIV-1 tat protein vaccine. Nat.
Med. 5, 643–650.
Carl, S., Iafrate, A. J., Lang, S. M., Stahl-Hennig, C., Kuhn, E. M., Fuchs,
D., Ma¨tz-Rensing, K., ten Haaft, P., Heeney, J. L., Skowronski, J., and
Kirchhoff, F. (1999). The acidic region and conserved putative protein
kinase C phosphorylation site in Nef are important for SIV replication
in rhesus macaques. Virology 257, 138–155.
Couillin, I., Connan, F., Culmann-Penciolelli, B., Gomard, E., Guillet, J. G.,
and Choppin, J. (1995). HLA-dependant variations in human immu-
nodeficiency virus Nef protein alter peptide/HLA binding. Eur. J. Im-
munol. 25, 728–732.
Couillin, I., Culmann-Penciolelli, B., Gomard, E., Choppin, J., Le´vy, J. P.,
Guillet, J. G., and Saragosti, S. (1994). Impaired cytotoxic T lympho-
cyte recognition due to genetic variations in the main immunogenic
region of the human immunodeficiency virus 1 NEF protein. J. Exp.
Med. 180, 1129–1134.Dalod, M., Dupuis, M., Deschemin, J. C., Sicard, D., Salmon, D., Del-
fraissy, J. F., Venet, A., Sinet, M., and Guillet, J. G. (1999). Broad,
Kintense anti-HIV ex vivo CD81 responses in HIV type 1-infected
patients: Comparison with anti-EBV responses and changes during
antiretroviral therapy. J. Virol. 73, 7108–7116.
eprez, B., Sauzet, J. P., Boutillon, C., Martinon, F., Tartar, A., Sergh-
eraert, C., Guillet, J. G., Gomard, E., and Gras-Masse, H. (1996).
Comparative efficiency of simple lipopeptide constructs for in vivo
induction of virus-specific CTL. Vaccine 14, 375–382.
isenlohr, L. C., Yewdell, J. W., and Bennink, J. R. (1992). Flanking
sequences influence the presentation of an endogenously synthe-
sized peptide to cytotoxic T lymphocytes. J. Exp. Med. 175, 481–487.
vans, D. T., O’Connor, D. H., Jing, P., Dzuris, J. L., Sidney, J., Da Silva, J.,
Allen, T. M., Horton, H., Venham, J. E., Rudersdorf, R. A., Vogel, T.,
Pauza, C. D., Bontrop, R. E., DeMars, R., Sette, A., Hugues, A. L., and
Watkins, D. I. (1999). Virus-specific cytotoxic T-lymphocyte responses
select for amino-acid variation in simian immunodeficiency virus Env
and Nef. Nat. Med. 5, 1270–1276.
lynn, J. N., Keating, P., Hosie, M. J., Mackett, M., Stephens, E. B., Beatty,
J. A., Neil, J. C., and Jarrett, O. (1996). Env-specific CTL predominate
in cats protected from feline immunodeficiency virus infection by
vaccination. J. Immunol. 157, 3658–3665.
allimore, A., Cranage, M., Cook, N., Almond, N., Bootman, J., Rud, E.,
Silvera, P., Dennis, M., Corcoran, T., Stott, J., McMichael, A., and
Gotch, F. (1995). Early suppression of SIV replication by CD81 Nef-
specific cytotoxic T cells in vaccinated macaques. Nat. Med. 1,
1167–1173.
oulder, P. J. R., Phillips, R. E., Colbert, R. A., McAdam, S., Ogg, G.,
Nowak, M. A., Giangrande, P., Luzzi, G., Morgan, B., Edwards, A.,
McMichael, A. J., and Rowland-Jones, S. (1997). Late escape from an
immunodominant cytotoxic T-lymphocyte response associated with
progression to AIDS. Nat. Med. 3, 212–217.
uy, B., Kie´ny, M. P., Rivie`re, Y., Le Peuch, C., Dott, K., Girard, M.,
Montagnier, L., and Lecocq, J. P. (1987). HIV F/39 orf encodes a
phosphorylated GTP-binding protein resembling an oncogene prod-
uct. Nature (Lond) 330, 266–269.
anke, T., Schneider, J., Gilbert, S. C., Hill, A. V. S., and McMichael, A.
(1998). DNA multi-CTL epitope vaccines for HIV and Plasmodium
falciparum: Immunogenicity in mice. Vaccine 16, 426–435.
arrer, T., Harrer, E., Kalams, S. A., Barbosa, P., Trocha, A., Johnson,
R. P., Elbeik, T., Feinberg, M. B., Buchbinder, S. P., and Walker, B. D.
(1996). Cytotoxic T lymphocytes in asymptomatic long-term nonpro-
gressing HIV-1 infection: Breadth and specificity of the response and
relation to in vivo viral quasispecies in a person with prolonged
infection and low viral load. J. Immunol. 156, 2616–2623.
uang, Y., Zhang, L., and Ho, D. D. (1995). Characterization of nef
sequences in long-term survivors of human immunodeficiency virus
type 1 infection. J. Virol. 69, 93–100.
ameson, S. C., Carbone, F. R., and Bevan, M. J. (1993). Clone-specific
T cell receptor antagonists of major histocompatibility complex class
I-restricted cytotoxic T cells. J. Exp. Med. 177, 1541–1550.
in, B. X., Bauer, D. E., Tuttleton, S. E., Lewin, S., Gettie, A., Blanchard,
J., Irwin, C. E., Safrit, J. T., Mittler, J., Weinberger, L., Kostrikis, L. G.,
Zhang, L., Perelson, A. S., and Ho, D. D. (1999). Dramatic rise in
plasma viremia after CD81 T cell depletion in simian immunodefi-
ciency virus-infected macaques. J. Exp. Med. 189, 991–998.
Kaslow, R. A., Carrington, M., Apple, R., Park, L., Munoz, A., Saah, A. J.,
Goedert, J. J., Winkler, C., O’Brien, S. J., Rinaldo, C., Detels, R., Blattner,
W., Phair, J., Erlich, H., and Mann, D. L. (1996). Influence of combina-
tions of human major histocompatibility complex genes on the
course of HIV-1 infection. Nat. Med. 2, 405–411.
Kaul, R., Plummer, F. A., Kimani, J., Dong, T., Kiama, P., Rostron, T., Njagi,
E., MacDonald, K. S., Bwayo, J. J., McMichael, A. J., and Rowland-
Jones, S. L. (2000). HIV-1-specific mucosal CD81 lymphocyte re-
sponses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Im-
munol. 164, 1602–1611.ent, S. J., Greenberg, P. D., Hoffman, M. C., Akridge, R. E., and
McElrath, M. J. (1997). Antagonism of vaccine-induced HIV-1-specific
KK
L
M
M
M
T
W
W
561TEMPORAL LOSS OF Nef-EPITOPE CTLCD41 T cells by primary HIV-1 infection: Potential mechanism of
vaccine failure. J. Immunol. 158, 807–815.
lenerman, P., Rowland-Jones, S., McAdam, S., Edwards, J., Daenke, S.,
Lalloo, D., Koˆppe, B., Rosenberg, W., Boyd, D., Edwards, A., Gian-
grande, P., Phillips, R. E., and McMichael, A. J. (1994). Cytotoxic T-cell
activity antagonized by naturally occurring HIV-1 Gag variants. Na-
ture (Lond) 369, 403–407.
uroda, M. J., Schmitz, J. E., Charini, W. A., Nickerson, C. E., Lifton, M. A.,
Lord, C. I., Forman, M. A., and Letvin, N. L. (1999). Emergence of CTL
coincides with clearance of virus during primary simian immunode-
ficiency virus infection in rhesus monkeys. J. Immunol. 162, 5127–
5133.
ill, N. L., Tevethia, M. J., Hendrickson, W. G., and Tevethia, S. S. (1992).
Cytotoxic T lymphocytes (CTL) against a transforming gene product
select for transformed cells with point mutations within sequences
encoding CTL recognition epitopes. J. Exp. Med. 176, 449–457.
alkovsky, M. (1996). HLA and natural history of HIV infection. Lancet
348, 142–1423.
iller, M. D., Lord, C. I., Stallard, V., Mazzara, G. P., and Letvin, N. L.
(1990). The GAG-specific cytotoxic T lymphocytes in rhesus monkeys
infected with the simian immunodeficiency virus of macaques. J. Im-
munol. 144, 122–128.
ortara, L., Gras-Masse, H., Venet, A., Guillet, J. G., and Bourgault-
Villada, I. (1999). Type 1 CD41 T-cell help is required for induction of
antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic
vaccine in rhesus macaques. J. Virol. 73, 4447–4451.
Mortara, L., Letourneur, F., Gras-Masse, H., Venet, A., Guillet, J. G., and
Bourgault-Villada, I. (1998). Selection of virus variants and emer-
gence of virus escape mutants after immunization with epitope
vaccine. J. Virol. 72, 1403–1410.
Myers, G., Korber, B., Wain-Hobson, S., and Smith, R. F. (1993). “Human
Retroviruses and AIDS.” Los Alamos National Laboratory, Los
Alamos, NM.
Ogg, G. S., Jin, X., Bonhoeffer, S., Dunbar, P. R., Nowak, M. A., Monard,
S., Segal, J. P., Cao, Y., Rowland-Jones, S. L., Cerundolo, V., Hurley, A.,
Markowitz, M., Ho, D. D., Nixon, D. F., and McMichael, A. J. (1998).
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma
load of viral RNA. Science 279, 2103–2106.
Phillips, R. E., Rowland-Jones, S., Nixon, D. F., Gotch, F. M., Edwards,
J. P., Ogunlesi, A. O., Elvin, J. G., Rothbard, J. A., Bangham, C. R. M.,
Rizza, C. R., and McMichael, A. J. (1991). Human immunodeficiency
virus genetic variation can escape cytotoxic T cell recognition. Na-
ture (Lond) 354, 453–459.
Pircher, H., Moskophidis, D., Rohrer, U., Bu¨rki, K., Hengartner, H., andZinkernagel, R. M. (1990). Viral escape by selection of cytotoxic T
cell-resistant virus variants in vivo. Nature (Lond) 346, 629–633.
Price, D. A., Goulder, P. J. R., Klenerman, P., Sewell, A. K., Easterbrook,
P. J., Troop, M., Bangham, C. R. M., and Phillips, R. E. (1997). Positive
selection of HIV-1 cytotoxic T lymphocyte escape variants during
primary infection. Proc. Natl. Acad. Sci. USA 94, 1890–1895.
Robinson, H. L., Montefiori, D. C., Johnson, R. P., Manson, K. H., Kalish,
M. L., Lifson, J. D., Rizvi, T. A., Lu, S., Hu, S. L., Mazzara, G. P., Panicali,
D. L., Herndon, J. G., Glickman, R., Candido, M. A., Lydy, S. L., Wyand,
M. S., and McClure, H. M. (1999). Neutralizing antibody-independent
containment of immunodeficiency virus challenges by DNA priming
and recombinant pox virus booster immunizations. Nat. Med. 5,
526–534.
Rowland-Jones, S. L., Dong, T., Fowke, K. R., Kimani, J., Krausa, P.,
Newell, H., Blanchard, T., Ariyoshi, K., Oyugi, J., Ngugu, E., Bwayo, J.,
MacDonald, K. S., McMichael, A. J., and Plummer, F. A. (1998).
Cytotoxic T cell responses to multiple conserved HIV epitopes in
HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102, 1758–1765.
Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A.,
Lifton, M. A., Racz, P., Tenner-Racz, K., Dalesandro, M., Montefiori,
B. J., Rieber, E. P., Letvin, N. L., and Reimann, K. A. (1999). Control of
viremia in simian immunodeficiency virus infection by CD81 lympho-
cytes. Science 283, 857–860.
Shugars, D. C., Smith, M. S., Glueck, D. H., Nantermet, P. V., Seillier-
Moiseiwitsch, F., and Swanstrom, R. (1993). Analysis of human im-
munodeficiency virus type 1 nef gene sequences present in vitro.
J. Virol. 67, 4639–4650.
Sloan-Lancaster, J., Evavold, B. D., and Allen, P. M. (1993). Induction of
T-cell anergy by altered T-cell-receptor ligand on live antigen-pre-
senting cells. Nature (Lond) 363, 156–159.
aswell, C. (1981). Limiting dilution assays for the determination of
immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126,
1614–1620.
agner, R., Leschonsky, B., Harrer, E., Paulus, C., Weber, C., Walker,
B. D., Buchbinder, S., Wolf, H., Kalden, J. R., and Harrer, T. (1999).
Molecular and functional analysis of a conserved CTL epitope in
HIV-1 p24 recognized from a long-term nonprogressor: Constraints
on immune escape associated with targeting a sequence essential
for viral replication. J. Immunol. 162, 3727–3734.
oodberry, T., Gardner, J., Mateo, L., Eisen, D., Medveczky, J., Ramshaw,
I. A., Thomson, S. A., French, R. A., Elliott, S. L., Firat, H., Lemonnier,
F. A., and Suhrbier, A. (1999). Immunogenicity of a human immuno-
deficiency virus (HIV) polytope vaccine containing multiple HLA A2
HIV CD81 cytotoxic T-cell epitopes. J. Virol. 73, 5320–5325.
